Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus

Journal of Diabetes and its Complications

Volumn 10, Issue 5, 1996, Pages 280-287

  Okuda, Yukichi ^a   Mizutani, Masakazu ^a   Ogawa, Masashi ^a   Sone, Hirohito ^a   Asano, Michiko ^a   Asakura, Yukari ^a   Isaka, Masaaki ^a   Suzuki, Seiji ^a   Kawakami, Yasushi ^a   Field, James B ^a,b   Yamashita, Kamejiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; EPADEL; ICOSAPENTAENOIC ACID; LIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HEMODYNAMICS; HUMAN; LEG; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL; VIBRATION SENSE;

EID: 0030578912     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(95)00081-X     Document Type: Article

References (31)

1. 1. Gabbay KH: The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836, 1973.
2. 2. Greene DA, Degesus PV, Winegrad AI: Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55:1326-1336, 1975.
3. 3. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M: Effects of a new aldose reductase inhibitor, (E)-3-carboxy methyl-5-[(2E)-Methyl-3-phenylpropenylidene] Phodanine (ONO-2235) on peripheral nerve disorders in streptozotocin Diabetic Rats. Diabetologia 24:290-292, 1983.
4. 4. Dyck PJ, Hansen S, Karnes J, O'Brien P, Yasuda H, Windebank A, Zimmerman B: Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 82:2513-2517, 1986.
5. 5. Johnson PC, Doll DW, Cromey DW: Pathogenesis of diabetic neuropathy. Ann Neurol 19:450-457, 1986.
6. 6. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJ, Word JD: Sural nerve oxygen tension in diabetes. BMJ 293:1053-1054, 1986.
7. 7. Dyerberg J, Bang HO, Stofferson E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet ii:117-119, 1978.
8. 8. Tamura Y, Hirai A, Terano T, Yoshida S, Takenaga M, Kitagawa H: Anti-thrombotic and anti-atherogenic action of eicosapentaenoic acid. J Jpn Circ 51:471-477, 1987.
9. 9. Sato M, Katsuki Y, Fukuhara K, Kawano H, Mizota M, Hamada Y, Kunihiro Y: Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets. Biol Pharm Bull 16:362-367, 1993.
10. 10. Ishiguro J, Tada T, Ogihara T, Mizota M, Mizuguchi K, Ohzawa N, Kosuzume H, Aizawa N: Metabolism of ethyl eicosapentaenoate (EPA-E) in rats and effect of its metabolites on ellagic acid-induced thrombus formation in the stenosed femoral artery of rabbits. Chem Pharm Bull 36:2158-2167, 1988.
11. 11. Okuda Y, Mizutani M, Ikegami T, Ueno E, Yamashita K: Hemodynamic effect of cilostazol on peripheral artery in patients with diabetic neuropathy. Arzneimittelforschung Drug Res 42:540-542, 1992.
12. 12. Bang HO, Dyerberg J: Plasma lipids and lipoproteins in greenlandic west coast eskimos. Acta Med Scand 192: 85-94, 1972.
13. 13. Jamal GA: Pathogenesis of diabetic neuropathy: The role of the n-6 essential fatty acids and their eicosanoid derivatives. Diabetic Med 7:574-579, 1990.
14. 14. Malasanos TH, Stacpoole PW: Biological effects of ω-3 fatty acids in diabetes mellitus. Diabetes Care 14:1160-1179, 1991.
15. 15. Cohen MP, Urdanivia E, Surma M, Ciborowski J: Non-enzymatic glycosylation of basement membranes. In vitro studies. Diabetes 30:367-371, 1981.
16. 16. Barnes AJ, Locke P, Scudder PR, Dormandy JA, Slack J: Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet ii:789-791, 1977.
17. 17. Shibata N: Clinical application of EPA preparations. Ischemic heart disease. Biomed Ther 25:79-88, 1991.
18. 18. Mortensen JZ, Schmidt EB, Nielsen Arl, Dyerberg J: The effect of N-6 and N-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. Thromb Haemost 50:543-546, 1983.
19. 19. Bonaa KH, Bjerve KS, Straume B, Gram IT, Thelle D: Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension: A population-based intervention trial from the Tromso study. N Engl J Med 322:795-801, 1990.
20. 20. Okuda Y, Mizutani M, Tsukahara K, Yamashita K: Eicosapentaenoic acid prevents the inhibition of myo-inositol uptake induced by high glucose concentration in cultured human endotheliae cells. Horm Metab Res 25:127-128, 1993.
21. 21. Holman RT: Essential fatty acids in nutritional disease. Chem Ind 5:704-709, 1981.
22. 22. Sinclair HM: Low phosphate arachidonic acid values in diabetic platelets [Letter]. BMJ 286:648, 1983.
23. 23. Lin CJ, Peterson T, Eichberg J: The fatty acid composition of glycerolipids in nerve, brain and other tissues of the streptozotocin diabetic rat. Neurochem Res 10: 1453-1465, 1985.
24. 24. Elliasson SG: Lipid synthesis in the peripheral nerves from alloxan diabetic rats. Lipids 1:237-240, 1966.
25. 25. Tilvis RS, Miettinen TA: Fatty acid compositions of serum lipids, red cells and platelets in insulin-dependent diabetic women. J Clin Endocrinol Metab 61:741-745, 1985.
26. 26. Mizutani M, Okuda Y, Yamashita K: High glucose causes dysfunction in human vascular endothelial cells and preventive effects of eicosapentaenoic acids, in Yasugi T, Nakamura H, Soma M (ed), Advances in Polyunsaturated Fatty Acid Research. New York, Elsevier, 1993, pp. 201-202.
27. 27. Juan H, Sametz W: Dihomo-γ-Linolenic acid increases the metabolism of eicosapentaenoic acid in perfused vascular tissue. Prost Leuk Med 19:79-86, 1985.
28. 28. Nassar BA, Huang YS, Manku MS, Das UN, Morse N, Horrobin H: The influence of dietary manipulation with n-3 and n-6 fatty acids on liver and plasma phospholipid fatty acids in rats. Lipids 21:652-656, 1986.
29. 29. Illingworth DR, Connor WE, Harris WS, Goodnight SH: The influence of dietary ω-3 fatty acids on plasma lipids and lipoproteins in human: Efficacy and mechanism. Reading University Conference on N3 Fatty acids. London, 1984, pp. 63.
30. 30. Harris WS, Connor WE, Inkeles SB, Illingworth DR: Dietary ω-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism 33:1016-1019, 1984.
31. 31. Simons LA, Hickie JB, Balasubramaniam S: On the effects of dietary n-3 fatty acids (MaxEPA) on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis 54:75-78, 1985.